Balyasny Asset Management
JSPR icon

Balyasny Asset Management’s Jasper Therapeutics JSPR Stock Holding History

Balyasny Asset Management’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-14,743
Closed -$277K – 3006
2024
Q3 		$277K Buy
+14,743
New +$294K ﹤0.01% 2474
2024
Q2 		– Sell
-8,417
Closed -$247K – 2847
2024
Q1 		$247K Buy
+8,417
New +$150K ﹤0.01% 2327

Other funds holding JSPR

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Balyasny Asset Management's JSPR Position: Q4 2024 in Review

Balyasny Asset Management sold out of Jasper Therapeutics (JSPR) in Q4 2024, closing a stake of 14,743 shares — an estimated $277K sold.

Balyasny Asset Management first reported a position in JSPR in Q1 2024 and held it in 2 quarters. The position peaked at $277K in Q3 2024. 87 funds tracked by Wall St. Rank hold JSPR as of Q4 2024.

  • Balyasny Asset Management reported no remaining Jasper Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Balyasny Asset Management sold 14,743 Jasper Therapeutics shares in Q4 2024, an estimated $277K.
  • Balyasny Asset Management first reported a position in Jasper Therapeutics in Q1 2024 and held it in 2 quarters.
  • Balyasny Asset Management's Jasper Therapeutics position peaked at $277K in Q3 2024.
  • 87 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q4 2024.

Based on Balyasny Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.